Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

Accelerate.EU Elevating the Future of Cancer care with Alpha Theranostics

Coordinator
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules Bordet, Belgium
Runs
1 October 2024 to 30 September 2029
Status
Running
EU funding
€8.0m
Total cost
€16.1m
Partners
17 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101173001

What the project is doing

In the project's own words, from its summary on CORDIS.

Accelerate. EU, a collaborative European initiative, envisions revolutionising theranostics through innovative targeted alpha-therapies (TATs) using astatine-211. A unique consortium will combine diagnostics with potent cytotoxic effects of alpha-particles to enable precise tumour radiation while minimising side effects. Accelerate. EU's core objectives are:Innovate theranostic solutions based on therapeutic and diagnostic pairs for hard-to-treat cancers, exploring the potential for simultaneous preclinical studies and early-phase clinical trials (i.e. co-clinical approach) to showcase the enhanced benefits of these approaches for cancer patients.•Establish a robust and sustainable EU manufacturing and treatment infrastructure for astatine-211, ensuring compliance with quality assurance and regulatory guidelines while streamlining the supply chain across the EU.•Produce comprehensive educational and training content to support the deployment of theranostic solutions, fostering knowledge dissemination, transfer and longevity/durabilityAccelerate.

EU strategically develop TATs to address unmet clinical needs in pancreatic, breast, and brain cancers. The co-clinical approach, incorporating concurrent clinical and preclinical studies, adds a breakthrough dimension to theranostics. Accelerate. EU pioneers 211At-theranostics establishing a resilient EU scale-up production network and empowering healthcare providers to offer TATs to cancer patients. Through the collaboration of experts from academia, industry and regulatory agencies, Accelerate.

EU's implements a visionary approach addressing clinical gaps, accelerating TAT theranostic development, supporting EU global leadership, with primary target to improve patient outcomes for lasting impact on EU cancer care.

Topics

Who is involved

OrganisationCityCountryRole
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules BordetAnderlechtBelgiumCoordinator
Ion Beam Applications SAOttignies Louvain La NeuveBelgiumParticipant
Studiecentrum Voor Kernenergie / Centre D'etude De L'energie NucleaireBruxelles / BrusselBelgiumParticipant
The Oncidium FoundationBruxellesBelgiumParticipant
Universite Libre De BruxellesBruxellesBelgiumParticipant
Forschungszentrum Julich GmbHJulichGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Tetrakit Technologies ApsKobenhavnDenmarkParticipant
Fundacion Centro De Tecnologias De Interaccion Visual Y Comunicaciones VicomtechDonostia San SebastianSpainParticipant
Groupement Interet Public ArronaxSaint HerblainFranceParticipant
Institut De Cancerologie De L'ouestAngersFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Narodowe Centrum Badan JadrowychOtwockPolandParticipant
Universidade De CoimbraCoimbraPortugalParticipant
Lablogic Systems LimitedSheffieldUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI